Paul M Arnaboldi

Dr. Paul M Arnaboldi

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2008 in Allergy
Verified
Journal Article
Closed access
PDF file
Franziska Roth-WalterFranziska Roth-Walter
Franziska Roth-Walter
MBM. C. Berin
M. C. Berin
PAPaul M Arnaboldi
Paul M Arnaboldi
CEC. R. Escalante
C. R. Escalante
SDS. Dahan
S. Dahan
LML. Mayer
L. Mayer

1 August 2008 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
LSLimin Shang
Limin Shang
MFMasayuki Fukata
Masayuki Fukata
NTNanthakumar Thirunarayanan
Nanthakumar Thirunarayanan
AMAndrea P. Martin
Andrea P. Martin
PAPaul M Arnaboldi
Paul M Arnaboldi
SLSergio A. Lira
Sergio A. Lira

24 June 2013 in Journal of Experimental Medicine
Verified
Journal Article
Open access
JYJianjun Yang
Jianjun Yang
RZRuihua Zhang
Ruihua Zhang
GLGeming Lu
Geming Lu
YSYu Shen
Yu Shen
LPLiang Peng
Liang Peng
HXHuabao Xiong
Huabao Xiong
RORγt is necessary for the generation of TH17 cells but the molecular mechanisms for the regulation of TH17 cells are still not fully understood. We show that activation of CD4+ T cells results in the expression of inducible nitric oxide synthase (iNOS). iNOS-deficient mice displayed enhanced TH17 cell differentiation but without major effects on either TH1 or TH2 cell lineages, whereas endothelial NOS (eNOS) or neuronal NOS (nNOS) mutant mice showed comparable TH17 cell differentiation compared with wild-type control mice. The addition of N6-(1-iminoethyl)-l-lysine dihydrochloride (L-NIL), the iNOS inhibitor, significantly enhanced TH17 cell differentiation, and S-nitroso-N-acetylpenicillamine (SNAP), the NO donor, dose-dependently reduced the percentage of IL-17–producing CD4+ T cells. NO mediates nitration of tyrosine residues in RORγt, leading to the suppression of RORγt-induced IL-17 promoter activation, indicating that NO regulates IL-17 expression at the transcriptional level. Finally, studies of an experimental model of colitis showed that iNOS deficiency results in more severe inflammation with an enhanced TH17 phenotype. These results suggest that NO derived from iNOS in activated T cells plays a negative role in the regulation of TH17 cell differentiation and highlight the importance of intrinsic programs for the control of TH17 immune responses.

2 February 2007 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
SDStephanie Dahan
Stephanie Dahan
Franziska Roth-WalterFranziska Roth-Walter
Franziska Roth-Walter
PAPaul M Arnaboldi
Paul M Arnaboldi
SAShradha Agarwal
Shradha Agarwal
LMLloyd Mayer
Lloyd Mayer

1 January 2011 in Cellular Immunology
Verified
Journal Article
Closed access
XOXinshou Ouyang
Xinshou Ouyang
ZYZhuoshun Yang
Zhuoshun Yang
RZRuihua Zhang
Ruihua Zhang
PAPaul M Arnaboldi
Paul M Arnaboldi
GLGeming Lu
Geming Lu
HXHuabao Xiong
Huabao Xiong

1 April 2013 in Clinical and Vaccine Immunology
Verified
Journal Article
Closed access
PDF file
PAPaul M Arnaboldi
Paul M Arnaboldi
RSRudra Seedarnee
Rudra Seedarnee
MSMariya Sambir
Mariya Sambir
SCSteven M. Callister
Steven M. Callister
JIJosephine A. Imparato
Josephine A. Imparato
RDRaymond Dattwyler
Raymond Dattwyler
Current serodiagnostic assays for Lyme disease are inadequate at detecting early infection due to poor sensitivity and nonspecificity that arise from the use of whole bacteria or bacterial proteins as assay targets; both targets contain epitopes that are cross-reactive with epitopes found in antigens of other bacterial species. Tests utilizing peptides that contain individual epitopes highly specific for Borrelia burgdorferi as diagnostic targets are an attractive alternative to current assays. Using an overlapping peptide library, we mapped linear epitopes in OspC, a critical virulence factor of B. burgdorferi required for mammalian infection, and confirmed the results by enzyme-linked immunosorbent assay (ELISA). We identified a highly conserved 20-amino-acid peptide epitope, OspC1. Via ELISA, OspC1 detected specific IgM and/or IgG in 60 of 98 serum samples (62.1%) obtained from patients with erythema migrans (early Lyme disease) at the time of their initial presentation. By comparison, the commercially available OspC peptide PepC10 detected antibody in only 48 of 98 serum samples (49.0%). In addition, OspC1 generated fewer false-positive results among negative healthy and diseased (rheumatoid arthritis and positive Rapid Plasma Reagin [RPR+] test result) control populations than did PepC10. Both highly specific and more sensitive than currently available OspC peptides, OspC1 could have value as a component of a multipeptide Lyme disease serological assay with significantly improved capabilities for the diagnosis of early infection.